Production (Stage)
Barinthus Biotherapeutics plc
BRNS
$0.654
-$0.156-19.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 4.34% | -153.14% | 52.08% | -9.31% | 10.43% |
| Total Depreciation and Amortization | 96.50% | -6.96% | 1.20% | 5.87% | -0.79% |
| Total Amortization of Deferred Charges | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Non-Cash Items | -83.29% | 356.63% | 86.46% | 110.29% | -86.66% |
| Change in Net Operating Assets | -100.90% | 199.08% | -1,150.27% | 13.31% | 111.81% |
| Cash from Operations | -213.88% | 171.91% | -51.57% | -1.56% | 39.69% |
| Capital Expenditure | 98.20% | -143.86% | 40.63% | 37.66% | -301.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 98.20% | -143.86% | 40.63% | 37.66% | -301.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.76% | 80.00% | 29.89% | -28.83% | 361.47% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -99.76% | 80.00% | 29.89% | -28.83% | 361.47% |
| Foreign Exchange rate Adjustments | 141.98% | -218.98% | 1,829.69% | 27.44% | -143.85% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -287.69% | 153.96% | 4.30% | -0.64% | 33.48% |